{ "ok": true, "cik": "1088856", "ticker": "CORT", "name": "CORCEPT THERAPEUTICS INC", "filings": [ { "form": "8-K", "filed": "2026-09-23", "items": [ "5.02 Departure or Election of Directors; Appointment of Officers", "7.01 Regulation FD Disclosure", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1088856/000119312526398561/0001193125-26-398561-index.htm" }, { "form": "10-Q", "filed": "2026-07-29", "items": [], "url": "https://www.sec.gov/Archives/edgar/data/1088856/000162828026050613/0001628280-26-050613-index.htm" }, { "form": "8-K", "filed": "2026-07-29", "items": [ "2.02 Results of Operations and Financial Condition", "7.01 Regulation FD Disclosure", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1088856/000162828026050607/0001628280-26-050607-index.htm" }, { "form": "8-K", "filed": "2026-06-17", "items": [ "8.01 Other Events", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1088856/000119312526274258/0001193125-26-274258-index.htm" }, { "form": "8-K", "filed": "2026-06-03", "items": [ "8.01 Other Events" ], "url": "https://www.sec.gov/Archives/edgar/data/1088856/000119312526254622/0001193125-26-254622-index.htm" }, { "form": "8-K", "filed": "2026-05-28", "items": [ "5.02 Departure or Election of Directors; Appointment of Officers", "5.07 Submission of Matters to a Vote of Security Holders", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1088856/000162828026038793/0001628280-26-038793-index.htm" } ], "events12m": 14, "sources": { "facts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0001088856.json", "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1088856" }, "license": "Figures as filed with the SEC. Card text CC BY 4.0, POPS4.", "notAdvice": "Reporting, not investment advice. No price targets, no buy or sell views.", "edgar": "🫧 Edgar looked up CORCEPT THERAPEUTICS INC ($CORT). Last filing: 8-K (5.02 Departure or Election of Directors; Appointment of Officers), 2026-09-23. 14 event filings (8-K) in the past twelve months.", "auditor": { "changes": [], "nonReliance": [], "restatedSince": null }, "metrics": { "fiscalYearEnd": "2025-12-31", "revenue": 761407000, "revenueGrowth1y": 0.12794352927233943, "revenueGrowthPerYear": 0.20099298702129298, "yearsOfData": 5, "operatingMargin": 0.058834499814159835, "operatingMarginPrior": 0.20287834794975113, "netMargin": 0.13087875472644722, "operatingCashFlow": 141996000, "capitalSpending": 211000, "freeCashFlow": 141785000, "researchAndDevelopment": 254908000, "researchShareOfRevenue": 0.3347854695320637, "cash": 120495000, "longTermDebt": null, "longTermDebtChange": null, "revenueHistory": [ { "fiscalYearEnd": "2021-12-31", "revenue": 365978000 }, { "fiscalYearEnd": "2022-12-31", "revenue": 401858000 }, { "fiscalYearEnd": "2023-12-31", "revenue": 482375000 }, { "fiscalYearEnd": "2024-12-31", "revenue": 675040000 }, { "fiscalYearEnd": "2025-12-31", "revenue": 761407000 } ], "totalEquity": 647805000, "totalAssets": 836651000, "equityRatio": 0.7742834228370014, "returnOnEquity": 0.15383024212533092, "dividendsPaid": null, "payoutRatio": null, "dividendPerShare": 0, "dividendYearsRising": 0, "dividendCut": false, "priceBased": "Dividend yield, price/earnings and price/book need a share price. The boards carry filings only, so they are not shown.", "earningsPerShare": 0.95, "sharesOutstanding": 119987000, "bookValuePerShare": 5.398959887321126, "revenuePerShare": 6.345745789127156, "range80": { "low": 742895620.3567606, "high": 1049581959.7293463, "baseline": 900499590.3485013, "n": 4309, "band": "b01", "bandLabel": "$100M–1B", "method": "v4.1", "credibility": 0.5, "growthYears": 4, "ownVolatility": 0.10855001729325939, "classVolatility": 0.1022985825903761, "volatility": 0.10547062684550357 }, "ifPaceHeld": { "low": 742895620.3567606, "high": 1049581959.7293463 } }, "edgarette": "🔖 Exposure: revenue $761.4M (FY2025). Experience: revenue up 12.8% on the year, up 20.1% a year over 4 years; operating margin 5.9%, down from 20.3%. Soundness: equity 77.4% of assets, return on equity 15.4%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $742.9M and $1.0B next year (method v4.1: its own 4-year record of growth weighed at 50% against $100M–1B filers; on a year the method never saw, 83.4% landed inside). In a shock year the stress range is $680.7M to $1.1B. A range, not a forecast. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin 5.9% against a -3.8% median; growth 12.8% against 13.7%.", "peers": { "sic": 2834, "sicDescription": "Pharmaceutical Preparations", "calendarYear": 2025, "minRevenue": 50000000, "depth": 4, "group": "2834", "growth": [ 0.1365, 111 ], "opMargin": [ -0.038, 114 ], "equityRatio": [ 0.4028, 118 ], "returnOnEquity": [ -0.0112, 100 ], "payoutRatio": [ 0.403, 13 ] }, "summary": "Corcept Therapeutics (CORT) grew revenue 12.8% in FY2025 to $761 million, operating margin 5.9% against a -3.8% median for pharmaceutical preparations, equity 77.4% of assets. Every figure is from the company’s own annual report filed with the SEC.", "chart": "
CORCEPT THERAPEUTICS INC against its own record and its peers
Operating marginPeer median -3.8%5.9%Revenue, on the yearPeer median 13.7%12.8%Equity of assetsPeer median 40.3%77.4%Return on equityPeer median -1.1%15.4%Gold tick: the median of 100–118 peers with $50M+ revenue in pharmaceutical preparations
", "chartHorizon": "
Handed back now, or kept to compound
Of each dollar of profitHanded back per share$0Revenue growth it managed12.8%last year, for comparison

Gold is paid out to shareholders; navy is kept in the business. Retained profit times return on equity is the pace a company can fund from itself. Facts from the filings, not a recommendation.

", "backtest": { "tests": 7, "hits": 6, "rate": 0.8571428571428571, "method": "v4", "byYear": { "2019": [ 0, 1 ], "2020": [ 1, 1 ], "2021": [ 1, 1 ], "2022": [ 1, 1 ], "2023": [ 1, 1 ], "2024": [ 1, 1 ], "2025": [ 1, 1 ] }, "note": "hindsight: the same credibility-weighted range on the company's own past years. Years 2018-2023 were used to fit or tune the method, so only 2025 outcomes are fully out of sample." }, "registry": { "logged": "2026-09-24T14:21:20.877Z", "hash": "bcf7009ffb2d87d0", "status": "open" }, "caution": "Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.", "schema": "pops4.edgarette.card/1", "card": { "summary": "Corcept Therapeutics (CORT) grew revenue 12.8% in FY2025 to $761 million, operating margin 5.9% against a -3.8% median for pharmaceutical preparations, equity 77.4% of assets. Every figure is from the company’s own annual report filed with the SEC.", "exposure": { "fiscalYearEnd": "2025-12-31", "revenue": 761407000, "totalDebt": null, "cash": 120495000 }, "experience": { "revenueGrowth1y": 0.12794352927233943, "revenueGrowthPerYear": 0.20099298702129298, "operatingMargin": 0.058834499814159835, "operatingMarginPrior": 0.20287834794975113, "netMargin": 0.13087875472644722, "freeCashFlow": 141785000 }, "soundness": { "equityRatio": 0.7742834228370014, "returnOnEquity": 0.15383024212533092, "payoutRatio": null, "dividendPerShare": 0, "dividendYearsRising": 0, "dividendCut": false, "note": "Dividend yield, price/earnings and price/book need a share price. The boards carry filings only, so they are not shown." }, "peers": { "sic": 2834, "sicDescription": "Pharmaceutical Preparations", "calendarYear": 2025, "minRevenue": 50000000, "depth": 4, "group": "2834", "growth": [ 0.1365, 111 ], "opMargin": [ -0.038, 114 ], "equityRatio": [ 0.4028, 118 ], "returnOnEquity": [ -0.0112, 100 ], "payoutRatio": [ 0.403, 13 ] }, "credibility": { "auditedYears": 5, "weight": "reasonable", "standard": "ASOP No. 25", "nonReliance": null, "auditorChange": null }, "range": { "low": 742895620.3567606, "high": 1049581959.7293463, "baseline": 900499590.3485013, "coverage": 0.8, "method": "v4.1", "basis": "next fiscal year revenue: baseline = revenue x (1 + mean of one-year and three-year pace); width = the company's own volatility of yearly growth, credibility-weighted against its size class (Buhlmann), scaled to the 80% target on 2023 and tested on 2024", "calibratedOn": { "companyYears": 4309, "sizeBand": "$100M–1B", "fitYears": [ 2018, 2022 ], "tuneYear": 2023, "testYear": 2024, "coverageOnTestYear": 0.8341 }, "credibility": { "weightOnOwnRecord": 0.5, "growthYears": 4, "ownVolatility": 0.10855001729325939, "classVolatility": 0.1022985825903761, "pricedVolatility": 0.10547062684550357, "k": 3 }, "stress": { "low": 680703149.6423877, "high": 1149506370.3929346, "basis": "the same range with widths set to hold 80% across 2018-2023, pandemic years included" }, "kind": "a calibrated range, not a forecast; no view on the share price", "track": { "backtest": { "tests": 7, "hits": 6, "rate": 0.8571428571428571, "method": "v4", "byYear": { "2019": [ 0, 1 ], "2020": [ 1, 1 ], "2021": [ 1, 1 ], "2022": [ 1, 1 ], "2023": [ 1, 1 ], "2024": [ 1, 1 ], "2025": [ 1, 1 ] }, "note": "hindsight: the same credibility-weighted range on the company's own past years. Years 2018-2023 were used to fit or tune the method, so only 2025 outcomes are fully out of sample." }, "registry": { "logged": "2026-09-24T14:21:20.877Z", "hash": "bcf7009ffb2d87d0", "status": "open" }, "scorecard": "https://www.pops4.com/boards/scorecard" } }, "caution": "Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.", "sources": { "facts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0001088856.json", "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1088856" } }, "definitions": { "operatingMargin": "Operating income divided by revenue.", "netMargin": "Net income divided by revenue.", "freeCashFlow": "Cash from operations minus spending on property and equipment.", "researchShareOfRevenue": "Research and development expense for the year as a share of revenue, both as filed.", "equityRatio": "Shareholders equity as a share of total assets, both as filed. Higher means less of the company is owed to someone else.", "returnOnEquity": "Net income for the year against shareholders equity at year end.", "payoutRatio": "Dividends paid as a share of net income, in the year the cash went out.", "dividendYearsRising": "Consecutive years, counted back from the last on record, in which dividend per share rose. A fall ends the run and is reported as dividendCut.", "revenueGrowthPerYear": "Compound annual growth between the first and latest fiscal years shown.", "credibility": "How much weight a record deserves, in the actuarial sense (ASOP No. 25): more audited years, more weight.", "peers": "Medians of SEC filers with $50M+ revenue in the same industry code (SIC), narrowest group with at least 8 filers, calendar-year figures from SEC XBRL frames.", "backtest": "The same if-the-pace-held arithmetic applied to the company's own past years, scored against what it actually reported next. Hindsight, and labelled so." } }